Want to see ABCL full AI Analyst Report?
Programs Under Contract
Shows the volume of active projects, reflecting the company's business momentum and potential future revenue as these programs progress.AbCellera's steady increase in programs under contract, reaching 203 by the end of 2023, reflects its strategic shift towards clinical stage biotech. Despite reduced new partnership activities, the company is focusing on advancing key programs like ABCL635 and ABCL575, supported by strong liquidity and a significant partnership with AbbVie. This transition, while contributing to high R&D expenses and declining revenue, positions AbCellera for future growth as it aims to leverage its TCE platform for new collaborations and clinical advancements.
Date | Programs Under Contract |
|---|---|
Dec 31, 2023 | 203.00 |
Sep 30, 2023 | 182.00 |
Jun 30, 2023 | 177.00 |
Mar 31, 2023 | 177.00 |
Dec 31, 2022 | 174.00 |
Sep 30, 2022 | 164.00 |
Jun 30, 2022 | 164.00 |
Mar 31, 2022 | 158.00 |
Dec 31, 2021 | 156.00 |
Sep 30, 2021 | 155.00 |